These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 28278708)

  • 1. Myelodysplastic syndrome with concomitant del(5q) and JAK2 V617F mutation transformed to acute myeloid leukemia with an additional chromosomal abnormality after a long-term treatment with lenalidomide.
    Oka S; Ono K; Nohgawa M
    Leuk Lymphoma; 2017 Oct; 58(10):2511-2513. PubMed ID: 28278708
    [No Abstract]   [Full Text] [Related]  

  • 2. Myelodysplastic syndrome with del (5q) and JAK2(V617F) mutation transformed to acute myeloid leukaemia with complex karyotype.
    Pich A; Godio L; Riera L; Cavaliere C; Kerim S; Bonello L; Francia di Celle P
    Ann Hematol; 2016 Feb; 95(3):525-7. PubMed ID: 26750119
    [No Abstract]   [Full Text] [Related]  

  • 3. Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation.
    Azaceta G; Calasanz MJ; Dourdil V; Bonafonte E; Izquierdo I; Palomera L
    Leuk Lymphoma; 2010 Oct; 51(10):1941-3. PubMed ID: 20846100
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.
    Möllgård L; Saft L; Treppendahl MB; Dybedal I; Nørgaard JM; Astermark J; Ejerblad E; Garelius H; Dufva IH; Jansson M; Jädersten M; Kjeldsen L; Linder O; Nilsson L; Vestergaard H; Porwit A; Grønbæk K; Hellström-Lindberg E
    Haematologica; 2011 Jul; 96(7):963-71. PubMed ID: 21719884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone marrow morphology predicts additional chromosomal abnormalities in patients with myelodysplastic syndrome with del(5q).
    Geyer JT; Verma S; Mathew S; Wang YL; Racchumi J; Espinal-Witter R; Subramaniyam S; Knowles DM; Orazi A
    Hum Pathol; 2013 Mar; 44(3):346-56. PubMed ID: 22995330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK2 V617F mutation is associated with 5q- syndrome in Chinese.
    Wong KF; Wong WS; Siu LL; Lau TC; Chan NP
    Leuk Lymphoma; 2009 Aug; 50(8):1333-5. PubMed ID: 19562618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide.
    Sugimoto Y; Sekeres MA; Makishima H; Traina F; Visconte V; Jankowska A; Jerez A; Szpurka H; O'Keefe CL; Guinta K; Afable M; Tiu R; McGraw KL; List AF; Maciejewski J
    J Hematol Oncol; 2012 Mar; 5():4. PubMed ID: 22390313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome.
    Mesa RA; Tefferi A; Li CY; Steensma DP
    Leukemia; 2006 Nov; 20(11):2063-4. PubMed ID: 16990762
    [No Abstract]   [Full Text] [Related]  

  • 9. The 5q deletion size in myeloid malignancies is correlated to additional chromosomal aberrations and to TP53 mutations.
    Stengel A; Kern W; Haferlach T; Meggendorfer M; Haferlach C
    Genes Chromosomes Cancer; 2016 Oct; 55(10):777-85. PubMed ID: 27218649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients.
    Santini V; Fenaux P; Giagounidis A; Platzbecker U; List AF; Haferlach T; Zhong J; Wu C; Mavrommatis K; Beach CL; MacBeth KJ; Almeida A
    Leukemia; 2021 Mar; 35(3):897-900. PubMed ID: 32661294
    [No Abstract]   [Full Text] [Related]  

  • 11. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
    Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
    Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation.
    Nomdedeu M; Maffioli M; Calvo X; Martínez-Trillos A; Baumann T; Díaz-Beyá M; Aguilar JL; Rozman M; Costa D; Esteve J; Cervantes F; Colomer D; Nomdedeu B
    Leuk Res; 2011 Sep; 35(9):1276-8. PubMed ID: 21764129
    [No Abstract]   [Full Text] [Related]  

  • 13. Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study.
    Uno S; Motegi Y; Minehata K; Aoki Y
    Int J Hematol; 2023 Oct; 118(4):432-442. PubMed ID: 37493867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment with azacitidine for the simultaneous occurrence of multiple myeloma and acute myeloid leukemia with concomitant del(5q) and the JAK2 V617F mutation.
    Oka S; Ono K; Nohgawa M
    Ann Hematol; 2017 Aug; 96(8):1411-1413. PubMed ID: 28577044
    [No Abstract]   [Full Text] [Related]  

  • 15. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
    Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refractory anaemia with ring sideroblasts associated with marked thrombocytosis (RARS-T) and JAK2(V617F) mutation transformed to acute myeloid leukaemia with chromosomal evolution including monosomy 7.
    Pich A; Godio L
    Leuk Res; 2010 Feb; 34(2):e69-70. PubMed ID: 19744708
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical picture and molecular disorders in myelodysplastic (MDP) syndromes].
    Rupniewska ZM
    Pol Arch Med Wewn; 1992 Mar; 87(3):197-208. PubMed ID: 1523148
    [No Abstract]   [Full Text] [Related]  

  • 18. The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q).
    Sekeres MA; Swern AS; Giagounidis A; List AF; Selleslag D; Mittelman M; Schlegelberger B; Göhring G; Li JS; Sugrue MM; Fenaux P
    Blood Cancer J; 2018 Sep; 8(10):90. PubMed ID: 30291223
    [No Abstract]   [Full Text] [Related]  

  • 19. Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide.
    Breccia M; Cannella L; Latagliata R; Nanni M; Santopietro M; Loglisci G; Ferretti A; Barzotti R; Oliva EN; Alimena G
    Leuk Res; 2011 Jun; 35(6):e69-70. PubMed ID: 21232796
    [No Abstract]   [Full Text] [Related]  

  • 20. CSNK1A1 mutations and isolated del(5q) abnormality in myelodysplastic syndrome: a retrospective mutational analysis.
    Smith AE; Kulasekararaj AG; Jiang J; Mian S; Mohamedali A; Gaken J; Ireland R; Czepulkowski B; Best S; Mufti GJ
    Lancet Haematol; 2015 May; 2(5):e212-21. PubMed ID: 26688096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.